DEVELOPMENT OF THE COMPOSITION AND TECHNOLOGY OF THE EXTEMPORANEOUS OINTMENT FOR TREATING URTICARIA

Oniper O. S., Zhyvora N. V., Chushenko V. N.
Scientific supervisors: assoc. prof. Zhyvora N. V., assoc. prof. Chushenko V. M.
National University of Pharmacy, Kharkiv, Ukraine
chushenkovn@gmail.com

Urticaria is the common name for the group of diseases. Its main clinical symptom is transient itchy wheals of various sizes, which are clearly structured and formed above the surface of the skin. Cold-induced urticaria is one of its types. The range of drugs of domestic and foreign production for treating dermatitis, namely urticaria, has been studied. The results have shown that there is a very small range of drugs to treat urticaria.

The aim of our work is to develop the composition and technology of the extemporaneous combined ointment for the treatment of cold-induced urticaria. Extemporaneous compounding of medicines makes possible an individual approach to a patient, which takes into account the peculiarities of the organism, the course of the disease, the symptoms of the disease and its stage. This is the main principle and advantage for preparing drugs in pharmacies.

Based on the literature and consultations with dermatologists of Kharkiv the formulation for the treatment of cold-induced urticaria has been selected. It is expedient to include the following active pharmaceutical ingredients (APIs) to the formulation: loratadine, lidocaine hydrochloride, methyluracil, salicylic acid and zinc oxide, which meet the requirements of the SPhU. The methods for testing the ointment are listed in the SPhU "Soft dosage forms". As a base for the ointment the emulsion base was used.

According to the studies conducted the technology of the ointment in pharmacies has been developed. The shelf life of ointments prepared *ex tempore* is 10 days; however, it does not correspond to the period of symptomatic therapy of cold-induced urticaria since its treatment can last up to one month. Therefore, extemporaneous compounding of the ointment has been conducted according to the requirements of Good Pharmacy Practice, which includes appropriate preparation of premises, APIs and excipients. The flowchart for preparing the ointment for the treatment of cold-induced urticaria has been developed. The study of organoleptic indicators of the samples of the combined ointment has been conducted. The stability of the ointment samples obtained by the direct inoculation method has been studied. Based on the results of the microbiological studies it has been found that the ointment samples are stable for 30 days, it allows defining the shelf life of 30 days.